4.7 Article

Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML

Related references

Note: Only part of the references are listed.
Article Oncology

Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML

Ilaria Gionfriddo et al.

Summary: Relapsed or refractory AML patients with NPM1 mutations face challenges in treatment, particularly in elderly and unfit individuals. Dactinomycin, a low-cost chemotherapeutic agent, shows potential as an alternative treatment option, possibly through its association with nucleolar stress. Further investigation in larger clinical studies is warranted.

LEUKEMIA (2021)

Review Hematology

NPM1-mutated acute myeloid leukemia: from bench to bedside

Brunangelo Falini et al.

BLOOD (2020)

Article Hematology

How I diagnose and treat NPM1-mutated AML

Brunangelo Falini et al.

BLOOD (2020)

Article Oncology

Mutant NPM1 Maintains the Leukemic State through HOX Expression

Lorenzo Brunetti et al.

CANCER CELL (2018)

Article Medicine, General & Internal

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

Timothy J. Ley et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Article Cell Biology

NESdb: a database of NES-containing CRM1 cargoes

Darui Xu et al.

MOLECULAR BIOLOGY OF THE CELL (2012)

Review Oncology

Nucleophosmin and cancer

Silvia Grisendi et al.

NATURE REVIEWS CANCER (2006)

Article Medicine, General & Internal

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

B Falini et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)